BRPI0813647A2 - Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados - Google Patents
Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionadosInfo
- Publication number
- BRPI0813647A2 BRPI0813647A2 BRPI0813647-5A2A BRPI0813647A BRPI0813647A2 BR PI0813647 A2 BRPI0813647 A2 BR PI0813647A2 BR PI0813647 A BRPI0813647 A BR PI0813647A BR PI0813647 A2 BRPI0813647 A2 BR PI0813647A2
- Authority
- BR
- Brazil
- Prior art keywords
- oxoalquil
- carbolins
- piperazinil
- tetrahydro
- beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94595907P | 2007-06-25 | 2007-06-25 | |
| PCT/US2008/068115 WO2009003003A2 (en) | 2007-06-25 | 2008-06-25 | Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0813647A2 true BRPI0813647A2 (pt) | 2014-12-23 |
Family
ID=40186267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0813647-5A2A BRPI0813647A2 (pt) | 2007-06-25 | 2008-06-25 | Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110002855A1 (pt) |
| EP (1) | EP2162451A4 (pt) |
| JP (1) | JP2010531364A (pt) |
| KR (1) | KR20100040872A (pt) |
| CN (1) | CN101784541A (pt) |
| AU (1) | AU2008268442A1 (pt) |
| BR (1) | BRPI0813647A2 (pt) |
| CA (1) | CA2690748A1 (pt) |
| IL (1) | IL202699A0 (pt) |
| MX (1) | MX2009013897A (pt) |
| WO (1) | WO2009003003A2 (pt) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101614723B1 (ko) | 2008-01-11 | 2016-04-22 | 알바니 몰레큘라 리써치, 인크. | Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌 |
| FR2950891B1 (fr) * | 2009-10-06 | 2012-11-09 | Sanofi Aventis | Derives d'azacarbolines 9h-pyrrolo[2,3-b:5,4-c']dipyridine, leur preparation et leur utilisation therapeutique |
| AU2010232644A1 (en) | 2009-03-31 | 2011-10-20 | Arqule, Inc. | Substituted tetrahydropyrazolo-pyrido-azepin compounds |
| US8618299B2 (en) | 2009-07-01 | 2013-12-31 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof |
| WO2011003007A1 (en) | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
| US9073925B2 (en) | 2009-07-01 | 2015-07-07 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
| JP2012532144A (ja) | 2009-07-01 | 2012-12-13 | アルバニー モレキュラー リサーチ， インコーポレイテッド | アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用 |
| MX338327B (es) | 2010-10-25 | 2016-04-12 | G1 Therapeutics Inc | Inhibidores de cdk. |
| US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| US8697700B2 (en) | 2010-12-21 | 2014-04-15 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof |
| US8993765B2 (en) | 2010-12-21 | 2015-03-31 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof |
| WO2012127885A1 (ja) | 2011-03-18 | 2012-09-27 | 小野薬品工業株式会社 | テトラヒドロカルボリン誘導体 |
| CN104203951B (zh) | 2012-03-16 | 2016-11-02 | 生命医药公司 | 肝x受体调节剂 |
| WO2013138568A1 (en) | 2012-03-16 | 2013-09-19 | Vitae Pharmaceuticals, Inc. | Liver x reception modulators |
| CA2868966C (en) | 2012-03-29 | 2021-01-26 | Francis Xavier Tavares | Lactam kinase inhibitors |
| ME03557B (me) | 2013-03-15 | 2020-07-20 | G1 Therapeutics Inc | Privremena zaštiтa normalnih ćelija током hemoterapije |
| CA2906157C (en) | 2013-03-15 | 2022-05-17 | G1 Therapeutics, Inc. | Highly active anti-neoplastic and anti-proliferative agents |
| ES2676698T3 (es) * | 2013-06-28 | 2018-07-24 | Alzprotect | Compuestos de carbolina útiles en el tratamiento de enfermedades neurodegenerativas |
| WO2015161288A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents |
| JP2017519737A (ja) * | 2014-05-26 | 2017-07-20 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換テトラヒドロピリドチエノピリミジン |
| EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| US11021514B2 (en) | 2016-06-01 | 2021-06-01 | Athira Pharma, Inc. | Compounds |
| EP3554494A4 (en) | 2016-12-19 | 2021-02-17 | Cellixbio Private Limited | INFLAMMATION TREATMENT COMPOSITIONS AND METHODS |
| MX2019008158A (es) | 2017-01-06 | 2019-12-09 | G1 Therapeutics Inc | Terapia de combinacion para el tratamiento del cancer. |
| EP3391886A1 (en) | 2017-04-19 | 2018-10-24 | Novartis AG | The use of a h3r inverse agonist for the treatment of shift work disorder |
| WO2019006393A1 (en) | 2017-06-29 | 2019-01-03 | G1 Therapeutics, Inc. | Morphic forms of git38 and methods of manufacture thereof |
| EP3681900A4 (en) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND THEIR USES |
| AU2019325685B2 (en) | 2018-08-24 | 2025-07-24 | Pharmacosmos Holding A/S | Improved synthesis of 1,4-diazaspiro(5.5)undecan-3-one |
| US10947253B2 (en) | 2019-08-05 | 2021-03-16 | Ankh Life Sciences Limited | Fused polycyclic dimers |
| KR20230066311A (ko) * | 2020-06-10 | 2023-05-15 | 델릭스 테라퓨틱스, 인크. | 삼환형 사이코플라스토겐 및 이의 용도 |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| US12129265B2 (en) | 2020-07-21 | 2024-10-29 | Ankh Life Sciences Limited | Therapeutic agents and uses thereof |
| WO2023023474A1 (en) * | 2021-08-16 | 2023-02-23 | Senya Pharmaceuticals, Inc. | Tr-beta modulators, pharmaceutical compositions, and therapeutic applications |
| CN114276359B (zh) * | 2022-01-05 | 2023-05-05 | 浙江大学 | 一种1,2,3,4-四氢苯并[4,5]呋喃[2,3-c]吡啶衍生物的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
| EA001539B1 (ru) * | 1996-11-27 | 2001-04-23 | Пфайзер Инк. | Амиды, ингибирующие секрецию аполипопротеина в (аро в) и/или микросомного протеина переноса триглицеридов (мтр) |
| AU5567000A (en) * | 1999-06-24 | 2001-01-09 | Toray Industries, Inc. | Alpha1b-adrenergic receptor antagonists |
| AR038366A1 (es) * | 2001-11-30 | 2005-01-12 | Schering Corp | Compuestos de 1,2,4-triazolo [1,5-c] pirimidinas sustituidas, antagonistas del receptor de adenosina a2a, composiciones farmaceuticas, el uso de dichos compuestos para la manufactura de un medicamento para el tratamiento de enfermedades del sistema nervioso central y un kit que comprende combinacion |
| WO2006072608A2 (en) * | 2005-01-03 | 2006-07-13 | Universitá Degli Studi Di Siena | Aryl piperazine derivatives for the treatment of neuropsychiatric disorders |
| US7851474B2 (en) * | 2005-08-02 | 2010-12-14 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
-
2008
- 2008-06-25 CA CA2690748A patent/CA2690748A1/en not_active Abandoned
- 2008-06-25 US US12/666,314 patent/US20110002855A1/en not_active Abandoned
- 2008-06-25 JP JP2010515057A patent/JP2010531364A/ja not_active Withdrawn
- 2008-06-25 KR KR1020107001683A patent/KR20100040872A/ko not_active Withdrawn
- 2008-06-25 WO PCT/US2008/068115 patent/WO2009003003A2/en not_active Ceased
- 2008-06-25 EP EP08780968A patent/EP2162451A4/en not_active Withdrawn
- 2008-06-25 CN CN200880104013A patent/CN101784541A/zh active Pending
- 2008-06-25 MX MX2009013897A patent/MX2009013897A/es not_active Application Discontinuation
- 2008-06-25 AU AU2008268442A patent/AU2008268442A1/en not_active Abandoned
- 2008-06-25 BR BRPI0813647-5A2A patent/BRPI0813647A2/pt not_active Application Discontinuation
-
2009
- 2009-12-13 IL IL202699A patent/IL202699A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009003003A2 (en) | 2008-12-31 |
| EP2162451A4 (en) | 2012-04-18 |
| US20110002855A1 (en) | 2011-01-06 |
| CN101784541A (zh) | 2010-07-21 |
| CA2690748A1 (en) | 2008-12-31 |
| EP2162451A2 (en) | 2010-03-17 |
| IL202699A0 (en) | 2010-06-30 |
| WO2009003003A3 (en) | 2009-02-19 |
| KR20100040872A (ko) | 2010-04-21 |
| AU2008268442A1 (en) | 2008-12-31 |
| MX2009013897A (es) | 2010-03-30 |
| JP2010531364A (ja) | 2010-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2019047I1 (no) | ravulizumab | |
| BRPI0813647A2 (pt) | Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados | |
| DE602008006301D1 (de) | Koaxialnadelanordnung | |
| BRPI0821573A2 (pt) | benzofuropirimidonas | |
| ATE501136T1 (de) | Imidazopyridinone | |
| DE502007001207D1 (de) | Elektrosaugkopf | |
| ATE514696T1 (de) | Diphenyl-dihydro-imidazopyridinone | |
| DE602008002772D1 (de) | Polyvinylpyrrolidonpulverzusammensetzungen | |
| DE112008003636A5 (de) | Mehrzuggruppierer | |
| BRPI0811451A2 (pt) | Exopolissacarídeo | |
| DE602008000923D1 (de) | Einzelwaferätzgerät | |
| DE602008000749D1 (de) | Buschschneider | |
| BRPI0814519A2 (pt) | Organopolissiloxano | |
| BRPI0814876A2 (pt) | Análogos de pirona fosforilados e métodos | |
| BRPI0815547A2 (pt) | Depsipeptídeos cícliocos | |
| BRPI0812840A2 (pt) | 2-imidazolinas | |
| DE602008001234D1 (de) | Bandmaterialzuführvorrichtung | |
| AT505058A3 (de) | Türschliesssystem | |
| BRPI0812994A2 (pt) | Microbiocidas | |
| DE602008004695D1 (de) | Katalysatorträgerwabe | |
| DE602008005950D1 (de) | Münzvereinzeler | |
| DE602008005589D1 (de) | Rliganden | |
| DE602008001674D1 (de) | Wimpernwickler | |
| DE112008001216A5 (de) | Magnetronplasmaanlage | |
| DE502008001694D1 (de) | Mitfahrhubwagen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |